Equities

Strides Pharma Science Ltd

Strides Pharma Science Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,549.60
  • Today's Change-0.35 / -0.02%
  • Shares traded196.91k
  • 1 Year change+218.23%
  • Beta1.0973
Data delayed at least 15 minutes, as of Nov 08 2024 10:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments2,8963,6071,842
Total Receivables, Net14,02415,00518,898
Total Inventory11,89212,00412,295
Prepaid expenses707639542
Other current assets, total1711,17941
Total current assets29,69032,43433,618
Property, plant & equipment, net9,58513,72615,136
Goodwill, net5,2945,1384,859
Intangibles, net5,2715,6316,250
Long term investments3,2874,5905,605
Note receivable - long term1,8581,8381,725
Other long term assets718334381
Total assets58,39866,38469,759
LIABILITIES
Accounts payable8,5169,82310,715
Accrued expenses519612569
Notes payable/short-term debt15,74213,30814,965
Current portion long-term debt/capital leases1,9963,5535,064
Other current liabilities, total2,0202,6052,803
Total current liabilities28,79329,90234,117
Total long term debt7,43113,43510,221
Total debt25,16930,29630,250
Deferred income tax403446357
Minority interest(539)(394)241
Other liabilities, total1,0538731,231
Total liabilities37,14244,26246,166
SHAREHOLDERS EQUITY
Common stock919903898
Additional paid-in capital18,23417,54517,326
Retained earnings (accumulated deficit)1,9983,0734,849
Treasury stock - common------
Unrealized gain (loss)(1823)(1300)(672)
Other equity, total1,8981,8791,172
Total equity21,25622,12323,592
Total liabilities & shareholders' equity58,39866,38469,759
Total common shares outstanding929090
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.